Conferencista Denise A. Galloway, Ph.D.

EDUCATION
1966-1970   BS, Biology, City College of New York, Biological Sciences
1970-1975   PhD, City University of New York, Molecular Biology
POSTGRADUATE TRAINING
1975-1978    Postdoctoral Fellow, Cold Spring Harbor Laboratory, New York
FACULTY POSITIONS HELD
1978-1983 Assistant Member, Fred Hutchinson Cancer Research Center, Seattle, WA.
1980-1985 Research Assistant Professor, Dept. of Pathology, University of Washington, Seattle, WA
1983-1987 Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA.
1985-1988 Research Associate Professor, University of Washington, Seattle, WA
1987-1998 Member, Program in Cancer Biology, PHS, Fred Hutchinson Cancer Research Center,
Seattle, WA.
1998- Member, Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
1988- Research Professor, University of Washington, Seattle, WA
1995- Research Professor, Department of Microbiology; Adjunct Research Professor,
Department of Pathology University of Washington, Seattle, WA
2000-2012 Program Head, Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, WA.
2010- Adjunct Research Professor, Pathobiology Graduate Program University of Washington,
Seattle, WA
2011-2013 Interim Director, Human Biology Division, Fred Hutchinson Cancer Research Center,
Seattle, WA.
2013-2018  Associate Director, Human Biology Division, Fred Hutchinson Cancer Research Center,
Seattle, WA.
2017 –  Director, Pathogen Associated Malignancies Integrated Research Center,
Fred Hutchinson Cancer Research Center, Seattle, WA.

TEACHING RESPONSIBILITIES
1971-1975 (Hunter College)

Course  Position
Principles of Biology I (undergraduate) Laboratory Instructor
Recitation Instructor
Principles of Biology II (undergraduate) Recitation Instructor
Molecular Biology (undergraduate Laboratory Instructor
Laboratory Co-coordinator
Recitation Instructor
1980 – (U. Washington/ FHCRC)
Tumor Biology (graduate)
Lectures on DNA viruses
Intro. to Pathology (undergraduate) Lectures on neoplasia
Medical Virology (undergraduate) Lectures on DNA viruses, viruses and cancer
General Pathology(graduate) Lectures on neoplasia
Epidemiology of Cancer (graduate) Lecture on neoplasia
Cell Cycle (graduate) Lectures on p53, senescence
Topics in Oncology (Medical students) Lectures on neoplasia
Sexually Transmitted Diseases (Post-graduate) Pathogenesis Track Co-coordinator,Lectures on HPVs, Molecular biology methods,
viral pathogenesis
Virology (graduate) Course co-organizerLectures on papilloma- and polyoma viruses and cancer,
DNA viruses
Pathobiology Course Organizer, Pathogen Associated Malignancies(PAM)

 

A. Fellows and Post-Doctoral Fellows in the Laboratory
1990- Joseph J. Carter, PhD, Post-Doctoral Fellow, Staff Scientist, Galloway Lab, Fred Hutch
2008-2015 Nicholas Wallace, PhD, Post-Doctoral Fellow, Assistant Professor, Kansas State University
2011-2016 Erin Scherer, PhD, Post-Doctoral Fellow, Senior Scientist, Center for Disease Control
2016-2018 Sujita Khanal, PhD, Post-Doctoral Fellow, Postdoctoral Fellow, Sanford Burnham Prebys
Medical Discovery Institute
2017-2018 David Skibinski, PhD, Staff Scientist, Research Scientist, Benaroya Institute
2018- Nicholas Duchemin, PhD, Post-Doctoral Fellow
2018- Leeya Pinder, MD, Clinical Research Fellow
2018-            Nicholas Salisbury, PhD, Post-Doctoral Fellow
B. Graduate Students
2013-2015 Gerald Mbarra, Graduate Student, Program in Pathobiology, Department of Global Health
2013-2015 Danny Columbara, Graduate Student, Program in Epidemiology,
1 year in my lab for thesis project
2016-present Kristine Dye, Graduate Student, Program in Pathobiology, Department of Global Health
C. Invited Talks, selected invitations (2013-2018)
2013 University of New Mexico, Albuquerque, NM, seminar, The Role of Merkel Cell  Polyomavirus in Merkel Cell Carcinoma

Australasian Society for Dermatology Research, Sydney Australia, Keynote Speaker,
The Role of Merkel Cell Polyomavirus in Merkel Cell Carcinoma Papillomaviruses and
Polyomaviruses of the Oral Cavity.

DNA Tumour Virus Meeting, Birmingham, UK Speaker – Overprinting a new MCPyV gene.
Institute of Medicine, Washington, DC, National Cancer Policy Summit, Speaker Infectious
Agents and Cancer.

14th International Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies: NIH, Program Committee

Workshop to evaluate HPV and Esophageal Cancer, Beijing, PRC, Invited Speaker

  2014 Oncogenesis and Translational Medicine for Cancer Treatment, University of Sao Paulo,
Brazil, Plenary Speaker, The basis of long term protection against HPV infection.Seminar, University of Colorado Medical School, Aurora, CO, The Role of Merkel Cell
Polyomavirus in Merkel Cell CarcinomaBaylor College of Medicine, Houston, TX, Seminar – The role of Merkel Cell polyomavirus
in cancer.International Conference on HPV, Polyomaviruses and UV in Skin Cancer, Novara Italy,
Keynote Speaker, Human Polyomavirus infections in Skin.

Asia Oceania Research Organization on Genital Infections and Neoplasia (AOGIN),
Beijing, PRC, Plenary speaker and Chair, HPV Carcinogenesis.

American Society for Microbiology, Boston, MA.  Plenary Speaker – Novel Pathogen
Associated Cancers.

29th International Papillomavirus Conference and Workshops, Seattle, WA,
Meeting organizer.

Cancers of the Skin, Edinburgh, Scotland, Plenary Speaker, Genus Beta HPVs disrupt
the response to DNA damage.

ASM Conference on Viral Manipulation of Nuclear Processes, Washington DC,
Invited Plenary, Viruses and the DNA Damage Response

2015 Review Committee, IARC Division of Infections and Cancer, Lyon, France

International Papillomavirus Conference and Workshops, Seville, Spain,
Planning Committee meeting.

Viruses & Cells Gordon Research Conference, Girones, Spain – Invited speaker
Phosphorylation of MCPyV ALTO

DNA Tumor Virus Meeting, Trieste, Italy, Speaker – HPV 16 E6 disrupts homology
dependent repair of DNA damage

International Papillomavirus Conference and Workshops, Lisbon, Portugal, Session Chair.

Huntsman Cancer Center, Salt Lake City, Utah – Seminar – The role of Merkel Cell
polyomavirus in cancer.

2016 International Symposium HIV and Emerging Infectious Diseases, Marseilles, France,

Plenary Speaker, New directions in HPV vaccines.

Emerging Oncogenic Viruses, Manduria, Italy, Invited Speaker, A single dose of HPV
vaccine boosts immunity after natural infection
AHNS Conference on Head and Neck Cancer, Seattle, WA, Session convener and speaker,
High risk HPVs disrupt DNA damage repair

International Conference on HPV and Polyomavirus is Skin Cancer, Maastricht,
Netherlands, Plenary Speaker, HPVs and DNA repair.

Keystone Symposium on Cellular Stress Responses and Infectious Agents, Santa Fe, N.M.
Speaker – HPVs and DNA damage repair

2017 31st International Papillomavirus Conference and Workshops, Cape Town, S.A., Executive Planning Committee, Session Chair, Plenary Speaker

Pioneers in Infectious Agents and Cancers, Naples, Italy, Invited Speaker,
HPV Cancers and the HPV vaccine.

DNA Tumor Virus Meeting, Birmingham, UK, Plenary Speaker – Preventive and Therapeutic
Approaches for DNA Tumor Viruses.

Global Health Dept. Symposium, University of Washington, History of the HPV Vaccine.

German CHS foundation, Heidelberg, GER, Plenary Speaker, Preventive and Therapeutic
Approaches for DNA Tumor Viruses.

2018 IDS/Virology Symposium, Fred Hutch/University of Washington, Seattle, Plenary Speaker,Preventive and Therapeutic Approaches for DNA Tumor Viruses.

NIAID, Laboratory of Viral Diseases, Bethesda, MD, Seminar, Long-Term Memory
Responses to HPV infection and Vaccination.

Pathobiology Program, Dept of Global Health, UW.  Seminar.  Preventive and Therapeutic
Approaches for DNA Tumor Viruses.

Institute for Molecular Virology Symposium, University of Minnesota, Plenary Speaker,
Long-Term Memory Responses to HPV infection and Vaccination.

Emerging Oncogenic Viruses, Manduria, Italy, Invited Speaker, Transforming Activity of
Merkel Cell Polyomavirus ST

American Society of Clinical Chemistry Symposium, Chicago, IL, Plenary Speaker,
History of the HPV Vaccine and current Directions

NCI Workshop, Shady Grove, MD– Discussion participant, Unanswered questions in HIV
associated malignancies.

International Papillomavirus Conference, Sydney, Australia, Plenary speaker, Boosting the
Response to Vaccination; also Chairing two sessions.

Pacific Northwest Head and Neck Cancer Symposium, Seattle, WA, Plenary Speaker,
Pathogenesis of HPV infections.

University of Massachusetts Medical School, Worcester MA, seminar, HPVs impair the
response to DNA damage

2019 University of New Mexico Cancer Center, Albuquerque, NM, seminar, HPVs impair the  response to DNA damage.

Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA,
Plenary Speaker, Pathogenesis of HPV infections.

Harvard University Medical School, Boston, MA, seminar, HPVs impair the response
to DNA damage

D. Presentations to community groups Friends of the Center
Community Liaison Project
FHCRC Board of Trustees
FHCRC Science for Life
UW Molecular Medicine Public Lecture
Microsoft CEO Spouse Symposium
FHCRC Planned Giving Committee
FHCRC  Science for Staff
FHCRC Science SpectraEDITORIAL RESPONSIBILITIES
1987-2002       Associate editor, Journal of Infectious Diseases
2006-2011       Associate editor:  Journal of General Virology
2008-               Associate editor, PloS Pathogens
EDITORIAL RESPONSIBILITIES
1987-2002 Associate editor, Journal of Infectious Diseases
2006-2011 Associate editor:  Journal of General Virology
2008- Associate editor, PloS Pathogens
EDITORIAL BOARDS
Journal of Virology, Virology, Virus Research, Journal of Cellular Physiology, Breast Cancer Research, Carcinogenesis
SPECIAL NATIONAL AND INTERNATIONAL RESPONSIBILITIES
1984-1987             Member – Experimental Virology Study Section, NIH
1987-1988             Chair – Experimental Virology Study Section, NIH
1992-1994             Member – Experimental Virology Study Section, NIH
1990-1994             Microbiology/-Virology Study Section, American Cancer Society
1984                      Co-Organizer – International Herpesvirus Workshop
1991                      Co-Organizer – International Papillomavirus Workshop
2000-2003             ASM’s – Chiron Corporation Biotechnology Research Award Nominating Committee.
2001-2006             Member, Chair – NCI: Basic and Preclinical Sciences PO1 study section
2005                      Chair- subcommittee I, IARC Monograph on HPVs, Lyon, France
2008 –                    Scientific Advisory Board, Johns Hopkins Univ. SPORE on Cervical Cancer
2009 – 2018           Canada Excellence Research Chairs Review Panel
2009 – 2013           Member, Chair – NIH, Virology A Study Section
2011 – 2013           Advisor, AIDS and Cancer Specimen Resource
2011 – 2012           AACR, Team Science Award Selection Committee
2012 –                    Scientific Advisory Board, Spanish National Cancer Research Centre (CNIO)
2012 –                    Program Committee, Malignancies in AIDS (ICMAOI)
2014                      Chair, International Papillomavirus Conference
2015                      Reviewer, IARC Programs on Infections and Cancer, Lyon, France
2015, 2018            Co-chair, NCI Outstanding Investigator Grant Review Committee
2015 – 2020           NCI, Board of Scientific Counselors- Basic
2016 – 2017          Exec. Committee, Int. Papillomavirus Workshop, Cape Town, SA
2017 –                    NCI BSA Subcommittee on HIV and AIDS Malignancies
2019 –                    NCI BSA Subcommittee on PreventionSPECIAL LOCAL RESPONSIBILITIES (recent):
1990 –                    Investigator, Center for AIDS and STDs, U.W.
1998 – 2011           Co-chair, Interdisciplinary Training Grant Selection Committee,
1997 – 2000          Chair, Associate Program Heads Committee, FHCRC
2000 – 2012           Program Head of Cancer Biology, FHCRC
2003 –                    Member, Seattle Cancer Consortium Steering Committee
2006 –                    Member, Advisory Board for Dr. R. Monnat’s PO1
2007 – 2009           Member, Virology Faculty Search Committee, UW
2009 – 2010           Chair, Human Biology Search Committee, FHCRC
2011 – 2013           Interim Division Director, Human Biology and Sr. VP, FHCRC
2013 –                    Associate Division Director, Human Biology
2014                      Member, Search Committee for FHCRC President
2015 – 2017           Deputy Director, Anogenital STTR Program
2016 –                    Immunotherapy Integrated Research Center Advisory Board
2017 –                    Director, Pathogen Associated Cancer Integrated Research Center
2018 –                    Member, Diversity Committee, Fred Hutch
2018 –                    Member, Shared Resources Committee, Fred Hutch
CURRENT CONSULTING:  Merck – Global Advisory Board for HPV
RESEARCH FUNDING
A.Current
2015-2019       Sponsor:  Merck Sharp & Dohme
Title:    Assessing the B Cell Response to Two vs. Three Doses of Gardasil 9.
Total Costs:  $992,461
Role:  PI: Denise A. Galloway, PhD
2016-2021       Sponsor: National Institute of Allergy and Infectious Diseases
Title:    HPV Capsid Antibodies
Total Costs: $2,403,685
Role:  PI: Denise A. Galloway, PhD
2017-2024       Sponsor: National Cancer Institute
Title:    R35 NCI Outstanding Investigator Award
Human Papillomavirus and Polyomavirus Associated Malignancies
Total Costs: $7,174,977
Role:  PI: Denise A. Galloway, PhD
2017-2022       Sponsor:  National Cancer Institute
Title:    Therapeutic Use of HPV L1 Vaccine in Anogenital Neoplasia: the VIVA trial.
Total Costs:  $23,776 (salary support only)
Role:  Co-Investigator; PI:  Margaret M. Madeleine, PhD
2017-2022       Sponsor:  National Cancer Institute
Title:    Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer.
Total Costs:  $23,776 (salary support only)
Role:    Co-Investigator; PI: Bruce Clurman, MD, PhD

2018-2021       Sponsor:  Bill and Melina Gates Foundation                               Title:    HPV single-dose vaccine efficacy study in Kenya

Total Costs:  $757,187
Role:    Co-Investigator, PI: Ruanne Barnabas, MBChB, DPhil

  2019-2023       Sponsor:  National Cancer Institute
Title:   Immunology and Immune Therapy for Merkel Cell Carcinoma
Total Costs:  $998,555 (Project 3 Co-PI)
Role:  Project 3 PI; P01 PI: Paul Nghiem, MD, PhD
B.   Pending 2019-2024        Sponsor: National Cancer Institute
Title:  Cervical Cancer Prevention in Peru and the Dominican Republic
Total Costs:  $11,568,913
Role:  PI Clinical Trial 1; PI’s: Margaret M. Madeleine, PhD & Ann Duerr, MD, PhD
C.Past Support (since 2013)       1989-2013       Sponsor:  National Cancer Institute
Title:  HPV: Biology, Clinical Significance and Epidemiology.
Total Costs:  $9,072,275 (Years 20-23)
Role:  PI:  Denise A. Galloway, PhD
2012-2014       NIAID/OHSU
Title:  NIAID Pacific Northwest Regional Center of Excellence for Biodefense
and Emerging Infectious Diseases.
Total Costs:  $370,000
Role:  Pilot Project PI; PI:  Jay A. Nelson, PhD
2012-2017       Sponsor:  NCI
Title:   Novel Pathogen Associated Cancers (PQ12)
Total Cost: $3,472,335
Role:  PI
BIBLIOGRAPHY

A. Publications in Refereed Journals

  1. Galloway, D.A. and Rudner, R.  Intrastrand secondary structure in Bacillus subtilis DNA.  J. Gen. Microbiology 111:353-361.  1979.
  2. Galloway, D.A., Lukanidin, E., Topp, W.C., and Sambrook, J.  Transformation of rat cells by the hybrid virus AD2HEY.  J. Gen. Virol. 42:330-356.  1979.
  3. Galloway, D.A., Fenoglio, C., Shevchuk, M. and McDougall, J.K.  Detection of herpes simplex RNA in human sensory ganglia.  Virology 95:615-628.  1979.
  4. Galloway, D.A., Copple, C.D. and McDougall, J.K.  Analysis of viral DNA sequences in hamster cells transformed by herpes simplex viral type 2.  Proc. Nat. Acad. Sci. 77:800-884.  1980.
  5. McDougall, J.K., Galloway, D.A. and Fenoglio, C.M.  Cervical carcinoma: Detection of herpes simplex virus RNA in cells undergoing neoplastic change.  Int. J. Cancer 25:1-8.  1980.
  6. McDougall, J.K., Massey, T. and Galloway, D.A.  Location and cloning of the HSV-2 thymidine kinase gene.  J. of Virol. 33:1221-1224.  1980.
  7. Galloway, D.A. and Swain, M.  Cloning of herpes simplex type 2 DNA fragments in a plasmid vector.  Gene 11:253-257.  1980.
  8. Galloway, D.A. and McDougall, J.K.  Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2.  J. Virol. 38:749-760.  1981.
  9. McDougall, J.K., Galloway, D.A., Crum, C., Levine, R., Richart, R. and Fenoglio, C.M.  Detection of nucleic acid sequences in cervical tumors.  Gynecologic Oncology 12:42-55.  1981.
  10. Galloway, D.A., Fenoglio, C.M. and McDougall, J.K.  Limited transcription of the herpes simplex virus genome when latent in human sensory ganglia.  J. Virol. 41:686-691.  1982.
  11. Galloway, D.A., Goldstein, L.C. and Lewis, J.B.  The identification of proteins encoded by a fragment of HSV-2 DNA that has transforming activity.  J. Virol. 42:530-537.  1982.
  12. Nelson, J.A., Fleckenstein, B., Galloway, D.A. and McDougall, J.K.  Transformation of rodent cells with a fragment of human cytomegalovirus DNA.  J. Virol. 43:83-91.  1982.
  13. McDougall, J.K., Crum, C.P., Fenoglio, C.M., Goldstein, L.C. and Galloway, D.A.  Herpesvirus specific RNA and protein in carcinoma of the uterine cervix.  Proc. Nat. Acad. Sci.  USA 79:3853-3857.  1982.
  14. Galloway, D.A. and McDougall, J.K.  The oncogenic potential of herpes simplex viruses: evidence for a “hit and run” mechanism.  Nature 301:21-24.  1983.
  15. Swain, M.A. and Galloway, D.A.  The nucleotide sequence of the herpes simplex virus type 2 thymidine kinase gene.  J. Virol. 46:1045-1050.  1983.
  16. Nelson, J.A., Fleckenstein, B., Jahn, G., Galloway, D.A. and McDougall, J.K.  Structure of the transforming region of human cytomegalovirus strain AD169.  J. Virol. 49:109-115.  1984.
  17. Galloway, D.A. and Swain, M.A.  Organization of the left-hand end of the herpes simplex virus type 2 Bgl II fragment N.  J. Virol. 49:724-730.  1984.
  18. Galloway, D.A., Nelson, J.A. and McDougall, J.K.  Small fragments of herpesvirus DNA with transforming activity contain IS-like structures.  Proc. Natl. Acad. Sci. USA 81:4736-4740.  1984.
  19. Draper, K.G., Frink, R.J., Devi, G.B., Swain, M., Galloway, D.A. and Wagner, E.K.  HSV-1 and HSV-2 homology in the region between 0.58-0.68 map units.  J. Virol. 52:615-623.  1984.
  20. Swain, M.A., Peet, R.W. and Galloway, D.A.  Characterization of the gene encoding the herpes simplex virus type 2 glycoprotein C and a comparison with the type 1 counterpart.  J. Virol. 53:561-569.  1985.
  21. Swain, M.A. and Galloway, D.A.  Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3’ co-terminal transcripts.  J. Virol. 57:802-808.  1986.
  22. Lockshon, D. and Galloway, D.A.  Cloning and characterization of oriL2, a large palindromic DNA replication origin of herpes simplex virus type 2.  J. Virol. 58:513-521.  1986.
  23. Brandt, C.R., Buonaguro, F.M., McDougall, J.K. and Galloway, D.A.  Plasmid mediated mutagenesis of a cellular gene in transfected eukaryotic cells.  Nucleic Acids Res. 15:561-573.  1987.
  24. Buonaguro, F.M., McDougall, J.K. and Galloway, D.A.  Characterization of the integration site of the CMV mtr in a tumor cell line.  Virology, 156:74-83.  1987.
  25. Halbert, C.L. and Galloway, D.A.  Identification of the E5 ORF of human papillomavirus type 16.  J. Virology 62:1071-1075.  1988.
  26. Jenison, S.A., Firzlaff, J.M., Langenberg, A. and Galloway, D.A.  Identification of immunoreactive antigens of human papillomavirus type 6b by using E. coli – expressed fusion proteins.  J. Virology 62:2115-2123.  1988.
  27. Firzlaff, J.M., Kiviat, N.B., Beckmann, A.M., Jenison, S.A. and Galloway, D.A.  Detection of human papillomavirus capsid antigen in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames.  Virology 164: 467-477.  1988.
  28. Lockshon, D. and Galloway, D.A.  Sequence and structural requirements of a herpes simplex virus DNA replication origin.  Molec. Cell. Biol. 8:4018-4027.  1988.
  29. Jenison, S.A., Yu, X.-p., Valentine, J.M. and Galloway, D.A.  Human antibodies react with an epitope of the HPV 6b L1 ORF which is distinct from the type common epitope.  J. Virol. 63:809-818.  1989.
  30. Kiviat, N., Koutsky, L., Paavonen, J., Galloway, D., Critchlow, C., Beckmann, A., McDougall, J., Peterson, M., Stevens, C., Lipinsky, C., Holmes, K.K.  Prevalence of genital papillomavirus infection among women attending a college student health clinic or a STD clinic.  J. Infect. Dis. 159:293-302.  1989.
  31. Firzlaff, J.M., Galloway, D.A., Eisenman, R.N. and Lüscher, B.  The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II.  The New Biologist 1:44-53.  1989.
  32. Christensen, N.D., Kreider, J.W., Cladel, N.M. and Galloway, D.A.  Immunological cross-reactivity to laboratory-produced HPV 11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV 6b and HPV 16 capsid proteins.  Virology, 175:1-9.  1990.
  33. Jenison, S.A., Yu, X.-p., Valentine, J.M., Koutsky, L.A., Christiansen, A.E., Beckmann, A.M. and Galloway, D.A.  Evidence of prevalent genital type human papillomavirus infections in adults and children.  J. Infect. Dis. 162:60-69.  1990.
  34. Galloway, D.A. and McDougall, J.K.  Alterations in the cellular phenotype induced by herpes simplex viruses.  J. Med. Virol. 31:36-42.  1990.
  35. Kiviat, N.B., Rompalo, A., Bowdin, R., Galloway, D.A., Holmes, K.K., Corey, L., Roberts, P.L. and Stamm, W.E.  Anal human papillomavirus infection among human immunodeficiency-seropositive and seronegative men.  J. Inf. Dis. 162:358-361.  1990.
  36. Kiviat, N.B., Koutsky, L.A., Critchlow, C.W., Galloway, D.A., Vernon, D.A., Peterson, M.L., McElhose, P.E., Pendras, S.J., Stevens, C.E. and Holmes, K.K.  Comparison of southern transfer hybridization and dot filter hybridization for detection of cervical human papillomavirus infection with types 6, 11, 16, 18, 31, 33, and 35.  Amer. J. of Clin. Pathol., 94:561-565.  1990.
  37. Halbert, C.L., Demers, G.W. and Galloway, D.A.  The E7 gene of HPV 16 is sufficient for immortalization of human epithelial cells.  J. Virol., 65:473-478.  1991.
  38. Beckmann, A.M., Sherman, K.J., Myerson, D., Daling, J.R., McDougall, J.K. and Galloway, D.A.  Comparative virologic studies of condylomata acuminata reveal a lack of dual infections with human papillomavirus.  J. Infect. Dis. 163:393-396.  1991.
  39. Jenison, S.A., Yu, X.-p., Valentine, J.M. and Galloway, D.A.  Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18.  J. Virol. 65:1208-1218.  1991.
  40. Yaegashi, N., Jenison, S.A., Valentine, J.M., Dunn, M., Taichman, L.B., Baker, D.A. and Galloway, D.A.  Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions.  J. Virol. 65:1578-1583.  1991.
  41. Carter, J.J., Yaegashi, N., Jenison, S.A. and Galloway, D.A.  Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae.  Virology 182:513-521.  1991.
  42. Yaegashi, N., Jenison, S.A., Batra, M. and Galloway, D.A.  Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11.  J. Virol. 66:2008-2019.  1992.
  43. Halbert, C.L., Demers, G.W. and Galloway, D.A.  The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells.  J. Virol. 66:2125-2134.  1992.
  44. Chen, L., Mizuno, M.T., Singhal, M.C., Hu, S.-L., Galloway, D.A., Hellström, I. and Hellström, K.E.  Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.  J. Immunol. 148:2617-2621.  1992.
  45. Mandelson, M.T., Jenison, S.A., Sherman, K.J., Valentine, J.M., McKnight, B., Daling, J.R. and Galloway, D.A.  The association of human papillomavirus antibodies with cervical cancer risk.  Cancer Epidemiology, Biomarkers and Prevention 1:281-286.  1992.
  46. Koutsky, L.A., Holmes, K.K., Critchlow, C.W., Stevens, C.E., Paavonen, J., Beckmann, A.M., DeRouen, T.A., Galloway, D.A., Vernon, D. and Kiviat, N.B.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.  New England Journal of Medicine, 327:1272-1278.  1992.
  47. *Hagensee, M., Yaegashi, N. and Galloway, D.A.  Self-assembly of HPV-1 capsids by expression of the L1 protein alone or by co-expression of the L1 and L2 capsid proteins.  J. Virol. 67:315-322.  1993.
  48. Yaegashi, N., Xi, L., Batra, M. and Galloway, D.A.  Sequence and antigenic diversity in two immunodominant regions of the L2 protein of human papillomavirus types 6 and 16.  J. Infect. Dis. 168:743-747.  1993.
  49. Chen, L., Ashe, S., Singhal, M.C. and Galloway, D.A., Hellström, I. and Hellström, K.E.  Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes.  Proc. Natl. Acad. Sci. USA 90:6523-6527.  1993.
  50. Xi, L-f., Demers, G.W., Kiviat, N.B., Kuypers, J., Beckmann, A.M. and Galloway, D.A.  Sequence variation in the non-coding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis.  J. Infect. Dis. 168:610-617.  1993.
  51. Carter, J.J., Hagensee, M., Taflin, M.C., Lee, S.K., Koutsky, L.A. and Galloway, D.A.  HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts.  Virology 195:456-462.  1993.
  52. Demers, G.W., Halbert, C.L. and Galloway, D.A. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 198: 169-174.  1994.
  53. Demers, G.W., Foster, S.A., Halbert, C.L. and Galloway, D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by HPV 16 E7.  Proc. Natl. Acad. Sci. USA 91:4382-4386.  1994.
  54. Carter, J.J., Hagensee, M.E., Lee, S.K., McKnight, B., Koutsky, L.A. and Galloway, D.A.  Use of HPV-1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts.  Virology 199: 284-291.  1994.
  55. Foster, S.A., Demers, G.W., Etscheid, B.G., Espling, E.S. and Galloway, D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68: 5698-5705.  1994.
  56. Hagensee, M.E., Olson, N.H., Baker, T.S., Galloway, D.A.  Three-dimensional structure of vaccinia virus-produced HPV-1 capsids.  J. Virol.   68: 1403-1405.  1994.
  57. Etscheid, B.G., Foster, S.A. and Galloway, D.A.  The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of its capacity to bind the tumor suppressor protein p53.  Virology 205: 583-585. 1994.
  58. Ostrow, R.S., Coughlin, S.M., McGlennen, R.C., Johnson, A.N., Ratterree, M.S., Scheffler, J., Yaegashi, Galloway, D.A., and Faras, A.J.  Serological and molecular evidence of rhesus papillomavirus type 1 infections in tissues from geographically distinct institutions. J. Gen.  Virol.  76: 293-299. 1995.
  59. Hagensee, M.E., Carter, J.J., Wipf, G.P., and Galloway, D.A.  Immunization of mice with HPV- vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies.  Virology 206: 174-182.  1995.
  60. Carter, J.J., Wipf, G., Hagensee, M.E., Taflin, M.C., McKnight, B., Habel, L.A., Lee, S.K., Kuypers, J., Kiviat, N. Daling, J.R., Koutsky, L.A., Watts, D.H., Holmes, K.K. and Galloway, D.A.  Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts.  J. Infect. Dis.  172:11-18.  1995.
  61. Russell, K.J., Wiens, L.W., Demers, G.W., Galloway, D.A., Plon, S.E., Groudine, M.  Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and competent cells. Cancer Research 55: 1639-1642.  1995.
  62. Paules, R.S., Levedaku, E.N., Wilson, S.J., Innes, C.L., Rhodes, N., Tlsty, T.D., Galloway, D.A., Donehower, L.A., Tainsky, M.A., Kaufman, W.K.  Defective G2 checkpoint function in cells from individuals with familial cancer syndromes.  Cancer Research. 55: 1763-1773.  1995.
  63. Xi, L.-F., Demers, G.W., Koutsky, L.A., Kiviat, N.B., Kuypers, J., Watts, D.H., Holmes, K.K., Galloway, D.A.  Analysis of human papillomavirus type 16 variants indicates establishment of a persistent infection.  J. Infect. Dis.  172:747-755. 1995.
  64. Levedaku, E.N., Kaufman, W.K, Alcorta, D.A., Galloway, D.A, Paules, R.S.  p21CIP1 is not required for the early G2 checkpoint response to ionizing radiation.  Cancer Research 55: 2500-2502.  1995.
  65. Wahl, A.F., Donaldson, K.L., Fairchild, C., Lee, F.Y.F., Foster, S.A., Demers, G.W., Galloway, D.A., Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis.  Nature Medicine 2: 72-79.  1996.
  66. Hawkins, D., Demers, G.W., Galloway, D.A.   Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.   Cancer Research 56:892-898. 1996.
  67. Foster, S.A., Galloway, D.A. Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene 12:1773-1779. 1996.
  68. Furukawa, T., Duguid, W.P., Rosenberg, L., Viallet, J., Galloway, D.A., Tsao, M.S. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papillomavirus 16.  Am. J. of Pathology 148:1763-1770.  1996.
  69. Daling, J.R., Madeleine, M.M., McKnight, B., Carter, J.J., Wipf, G.C.,   Ashley, R., Schwartz, S.M., Beckmann, A.M., Hagensee, M.E., Mandelson, M.T., Galloway, D.A.  The relationship of human papillomavirus – related cervical tumors to cigarette smoking, oral contraceptive use and prior herpes simplex -2 infection. Cancer Epidemiology, Biomarkers and Prevention 5:541-548. 1996.
  70. Carter, J.J., Koutsky, L.A., Wipf, G.C., Christensen, N.D., Lee,S.-K., Kuypers, J., Kiviat, N.B., Galloway, D.A.  The natural history of HPV 16 capsid antibodies among a cohort of university women.  J. Infect. Dis. 174:927-936. 1996.
  71. Demers, G.W., Espling, E., Harry, J.B., Etscheid, B.G., Galloway, D.A.   Abrogation of growth arrest signals by HPV 16E7 is mediated by sequences necessary for transformation.   J. Virol. 70:6862-6869. 1996.
  72. Christensen, N.D., Dillner, J., Eklund, C., Carter, J.J., Wipf, G.C., Reed, C.A., Cladel, N.M., Galloway, D.A. Surface conformational and linear epitopes on HPV 16 and HPV 18 L1 virus-like particles as defined by monoclonal antibodies.  Virology 223:174-184. 1996.
  73. Ullman, C.G., Haris, P.I., Galloway, D.A., Emery, V.C., Perkins, S.J. Predicted a-helix/b-sheet secondary structures for the xinc binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7.  Biochem. J. 319:229-239.  1996.
  74. Russell, K.J., Wiens, L.W., Demers, G.W., Galloway, D.A., Le, T., Rice, G.C., Bianco, J.A., Singer, J.W., Groudine, M. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines.  Int. J. Rad. Onc. Biol. Phys. 36:1099-1106.  1996.
  75. Ellis, J.R.M., Etherington, I., Galloway, D.A., Luesley, D., Young, L.S. Antibody responses to HPV 16 virus-like particles in women with CIN infected with a variant HPV 16.  Lancet 349: 1069- 1070. 1997.
  76. Xi, L.F., Koutsky, L.A., Galloway, D.A., Kuypers, J., Hughes, J.P., Wheeler, C.M., Holmes, K.K., Kiviat,N.B.  Risk of cervical intraepithelial neoplasia grade 2-3 in relation to human papillomavirus type 16 variants. J. Natl. Cancer Instit.  89:796-802. 1997.
  77. Funk, J.O., Waga, S., Harry, J.B., Espling, E., Stillman, B., Galloway, D.A.  Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV 16 E7 oncoprotein.  Genes and Development 11: 2090-2100. 1997.
  78. Hagensee, M.E., Kiviat, N.B., Critchlow, C.W., Hawes, S.E., Kuypers, J., Holte, S., Galloway, D.A.  Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men.       J. Infect. Dis.  176: 625-632. 1997.
  79. LePoole, I.C., van den Berg, F.M., van den Wijngaard, R.M., Galloway, D.A., van Amstel, P.J., Buffing, A.A., Smits, H.L., Westerhof, W., Das, P.K.  Generation of a human melanocyte cell line by introduction of HPV 16 E6 and E7 genes.  In Vitro Cell. And Dev. Biol. 33:42-49. 1997.
  80. Kaufmann, W.K., Schwartz. J.L., Hurt, J.C., Byrd, L.L., Galloway, D.A., Levedaku, E., Paules, R.S. Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing HPV 16 E6.  Cell Growth and Diff. 8: 1105-1114. 1997.
  81. Madeleine, M.M., Daling, J.R., Carter, J.J., Wipf, G.C., Schwartz, S.M., McKnight, B., Kurman, R.J., Beckmann, A.M., Hagensee, M.E., Galloway, D.A. Cofactors with human papillomavirus in a population-based study of vulvar cancer.  J. Natl. Cancer Institute 89:1516-1523.  1997.
  82. Martin, L.G., Demers. G.W., Galloway, D.A.   Disruption of the G1/S transition in HPV 16 E7 expressing cells is associated with altered regulation of cyclin E.  J. Virol. 72: 975-985. 1998.
  83. Watts, D.H., Koutsky, L.A., Holmes, K.K., Goldman, D., Kuypers, J., Kiviat, N.B., Galloway, D.A.  Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study.   Am. J Obstet. Gynecol. 178: 365-373. 1998.
  84. Foster, S.A., Wong, D.J., Barrett, M.T., Galloway, D.A.  Inactivation of p16 in human mammary epithelial cells by CpG island methylation.  Molec. and Cell Biol. 18:1793-1801.  1998.
  85. Kulski, J.K., Sadleir, J.W., Kelsall, S.R., Cicchini, M.S., Shellam, G., Peng, S.W., Qi, Y.M., Galloway, D.A., Zhou, J., Frazer, I.H.  Type specific and genotype cross-reactive B epitopes of the L1 protein of HPV 16 defined by a panel of monoclonal antibodies.  Virology. 243:275-282.  1998.
  86. Xi, L.F., Critchlow, C.W., Wheeler, C.M., Koutsky, L.A., Galloway, D.A., Kuypers, J., Hughes, J.P., Hawes, S.E., Surawicz, C., Goldbaum, G., Holmes, K.K., Kiviat, N.B.  Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants.  Cancer Research 58:3839-3844. 1998.
  87. Schwartz, S.M., Daling, J.R., Doody, D.R., Wipf, G.C., Carter, J.J., Madeleine, M.M., Mao, E.-J., Huang, S., Beckmann, A.M., McDougall, J.K., Galloway, D.A. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J. Natl. Cancer Institute 90: 1626-1636.  1998.
  88. *Kiyono, T., Foster, S.A., Koop, J.I., McDougall, J.K., Galloway*, D.A. Klingelhutz, A.J., Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.  Nature. 396: 84-86. 1998.  * corresponding author
  89. Marrazzo, J.M., Stine, K., Kuypers, J.M., Grubert, T.A., Galloway, D.A., Handsfield, H.H., Kiviat, N.B., Koutsky, L.A.  Genital human papillomavirus infection in women who have sex with women.  J. Infect. Dis.  178: 1604-1609.  1998.
  90. Wong, D.J.  Foster, S.A., Galloway, D.A., Reid, B.J.  Development of a region-specific methylation pattern in the p16 CpG island.  Mol. Cell Biol.  19: 5642-5651. 1999.
  91. Passalaris, T.M., Benanti, J., Gewin, L., Kiyono, T., Galloway, D.A. The G2 checkpoint is maintained by redundant pathways.  Mol. Cell. Biol. 19: 5872-5881. 1999.
  92. Madeleine, M.M., Shera, K., Schwartz, S.M., Daling, J.R., Galloway, D.A., Wipf, G.C., Carter, J.J., McDougall, J.K.  The p53 Arg72Pro polymorphism, HPV, and invasive squamous cell cervical cancer:  A population-based study.   Cancer Epidemiol Biomarkers & Prev., 2: 225-227.  2000.

  93. Hagensee, M.E., Koutsky, L.A., Lee, S.-K., Grubert, T., Kuypers, J., Kiviat, N.B., Galloway, D.A. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions.   J. Infect. Dis. 181:1234-1239.  2000.
  94. Carter, J. J., Koutsky, L.A., Hughes, J.P., Lee, S.-K., Kuypers, J., Kiviat, N.B., Galloway, D.A.  Comparison of HPV 16, 18 and 6 capsid antibody responses following incident infection.  J. Infect. Dis. 181: 1911-1919. 2000.

  95. McShea, A., Samuel, T., Eppel, J.T., Galloway, D.A., Funk, J.O.  Identification of CIP-1 associated regulator of cyclin B (CARB), a novel p21 binding protein acting in the G2 phase of the cell cycle. J Biol Chem. 275(30):23181-6. 2000.
  96. Madeleine, M.M., Daling, J.R., Schwartz, S.M., Shera, K., Carter, J.J., Wipf, G.C., McKnight, B., Critchlow, C.W., McDougall, J.K., Porter, P., Galloway, D.A. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix.  Cancer Epidemiol Biomarkers Prev 10: 171-177. 2001.
  97. Schwartz, S.M., Daling, J.R., Shera, K.A., Madeleine, M.M., McKnight, B., Galloway, D.A., Porter, P.L. McDougall, J.K. Human Papillomavirus and prognosis of invasive cervical cancer: a population-based study.  Journal of Clinical Oncology, 19:1906-1915.  2001.
  98. Carter, J.J., Madeleine, M.M., Shera, K., Schwartz, S.M., Cushing-Haugen, K.L., Wipf, G.C., Porter, P., Daling J. R., McDougall, J.K., Galloway, DA.  Human papillomavirus type 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Research, 61: 1934-1940. 2001.
  99. Helt, A.M., Galloway, D.A.  Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.  J. Virol. 75: 6737-6747. 2001.
  100. Gewin, L.C., Galloway, D.A.  E box-dependent activation of telomerase by HPV 16E6 does not require induction of c-myc.  J. Virol. 75:7198-7201. 2001.
  101. Starr, J.R., Daling, J.R., Fitzgibbons, E.D., Madeleine, M.E., Ashley, R., Galloway, D.A., Schwartz, S.M.  Serologic Evidence of herpes simplex virus 1 infection and oropharyngeal cancer risk. Cancer Research, 61:8459-8464. 2001.
  102. Daling, J.R., Madeleine, M.M., Schwartz, S.M., Shera, K., Carter, J.C., McKnight, B., Porter, P., Galloway, D.A., McDougall, J.K., Tamimi, H.  A population-based study of squamous cell vaginal cancer: HPV and co-factors.  Gynecologic Oncology, 84:263-270. 2001.
  103. Xi, L.-F., Carter, J.J., Galloway, D.A., Kuypers, J., Hughes, J.P., Lee, S.-K., Adam, D.E., Kiviat, N.B., Koutsky, L.A.  Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev. 11(4):343-51. 2002.
  104. Kaufmann, W.F., Campbell, C.B., Simpson, D.A., Deming, P.B., Filatov, L., Galloway, D.A., Zhao, X.J., Creighton, A.M., Downes, C.S.  Degradation of ATM-independent decatenation checkpoint function in human cells is secondary to inactivation of p53 and correlated with chromosomal destabilization.  Cell Cycle. 1: 210-219.  2002.
  105. Helt, A.M., Funk, J.O., Galloway, D.A.  Inactivation of both Rb and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to abrogate cell cycle arrest in human epithelial cells.  J. Virol. 76: 10559-10568.  2002.
  106. Benanti, J.A., Williams, D.K., Robinson, K.L., Ozer, H.L., Galloway, D.A.  Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1.  Molecular and Cellular Biology 22:7385-7397. 2002.
  107. Madeleine, M.M., Brumback, B., Cushing-Haugen, K., Smith, A.J., Nelson, J.L., Schwartz, S.M., Daling, J.R., Galloway, D.A. Class II HLA Alleles and the risk of squamous cell cervical cancer in a population-based study.   J. Infect. Dis. 186: 1565-1574.  2002.
  108. Helt, A. M., Galloway, D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.  Carcinogenesis 24:159-169.  2003.
  109. Onda, T., Carter, J.J., Koutsky, L.A., Hughes, J.P., Lee, S.-K., Kuypers, J., Kiviat, N.B., Galloway, D.A.  Characterization IgA response among women with incident HPV 16 infection.  Virology, 312(1):213-21.  2003.
  110. Rosenblatt, K.A., Carter, J.J., Iwasaki, L.M., Galloway, D.A., Stanford, J.L.  Serologic evidence of human papillomavirus 16 or 18 infection and risk of prostate cancer.  Cancer Epidemiol Biomarkers Prev. 12(8):763-768.  2003.
  111. Carter, J.J., Madeleine, M.M., Wipf, G.C., Garcea, R.L., Pipkin, P.A., Minor, P.D., Galloway, D.A. Lack of serologic evidence for prevalent SV40 infection in humans.  Journal of the National Cancer Institute, 95 (20) 1522-1530. 2003.
  112. Carter, J.J., Wipf, G.C., Benki, S., Christensen, N.D. Galloway, D.A.  Identification of a human papillomavirus 16-specific epitope on the C-terminal arm of the major capsid protein (L1).  J. Virol.  77(21):11625-11632. 2003.
  113. Grandori, C., Robinson, K., Galloway, D.A., Swisshelm, K. Functional link between Myc and the Werner gene in tumorigenesis.  Cell Cycle 3: 1-4. 2003.
  114. Benanti, J.A., Galloway, D.A., Normal human fibroblasts are resistant to RAS-induced senescence.  Molecular and Cellular Biology, 24:2842-2852. 2004.
  115. Daling, J.R., Madeleine, M.M., Johnson, L.G., Schwartz, S.M., Shera, K.A., Wurscher, M.A., Carter, J.J., Porter, P.L., Galloway, D.A., McDougall, J.K.  Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer.  Cancer, 101: 270-280. 2004.
  116. Shah, K., Galloway, D.A., Knowles, W., Viscidi, R.  SV40 and human cancer: a review of serological data.  Reviews in Medical Virology 14: 231-239.  2004.
  117. Engels,E.A., Viscidi, R.P.,  Galloway, D.A.,  Carter, J.J., Cerhan, J.R., Davis, S., Cozen, W., Severson, R.K., de Sanjose, S., Colt, J. S., Hartge, P.  Case-control study of simian virus 40 and non-Hodgkin’s lymphoma in the United States.  Journal of the National Cancer Institute, 96:1368-1374., 2004.
  118. Gewin, L.C., Myers, H., Kiyono, T., Galloway, D.A.  Identification of a novel telomerase repressor that interacts with the human papillomavirus E6/E6ap complex.  Genes & Development, 18:2269-2282.  2004.

  119. Benanti, J. A., Galloway, D.A.  The normal response to RAS: senescence or transformation? Cell Cycle 3:715-717, 2004.

  120. Loubiere LS, Lambert NC, Madeleine MM, Porter AJ, Mullarkey ME, Pang JM, Galloway DA, Furst DE, Nelson JL. HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women. Rheumatology. 44:318-22, 2005.
  121. Mullarkey ME, Stevens AM, McDonnell WM, Loubiere LS, Brackensick JA, Pang JM, Porter AJ, Galloway DA, Nelson JL. Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis. Tissue Antigens 65:199-205, 2005.
  122. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol.: 7(3):311-318, 2005.
  123. Orozco, J.J., Carter, J.J., Koutsky, L.A., Galloway, D.A. Human sera react with a complex set of epitopes on HPV 6 L1 capsomers.   J. Virology 79(15):9503-14, 2005.

  124. Daling, J.R., Madeleine M.M., Johnson, L.G., Schwartz, S.M., Shera, K.A., Wurscher, M.A., Carter, J.J., Porter, P. L., Galloway, D.A., McDougall, J.K., Krieger, J.N., Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. International Journal of Cancer. 116(4):606-16, 2005.
  125. Buchinsky, F.J., Carter, J.J., Wipf, G.C., Hughes, J.P., Koutsky, L.A., Galloway, D.A. Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women.  J Clin Virol. 35(4):450-3. 2006.
  126. Ferguson, M., Heath, A., Johnes, S., Pagliusi, S., Dillner, J., on behalf of the collaborative study group participants (includes D.A. Galloway).  Results of the first WHO international collaborative study on the standardisation of the detection of antibodies to human papillomaviruses. Int J Cancer 118(6):1508-14. 2006.
  127. Carter, J.J., Wipf, G.C., Madeleine, M.M., Schwartz, S.M., Koutsky, L.A., Galloway, D. A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol. 80(10):4664-72.  2006.
  128. Xi, L.F., Kiviat, N.B., Hildesheim, A., Galloway, D.A., Wheeler, C.M., Ho, J. Koutsky, L.A. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J. Natl. Canc. Inst. 98 (15): 1045-1052. 2006.

  129. Madeleine, M.M., Anttila, T., Daling, J.R., Saikku, P., Leinonen, M., Carter, J.J., Wurscher, M., Johnson, L.G., Galloway, D.A., Schwartz, S.M.  Risk of cervical cancer associated with Chlamydia trachomatis by histology, cofactors and HPV type.  Int. J. Cancer, 120 (3): 650-655. 2007.

  130. Haga, K., Ohno, S-i., Yugawa, T., Narisawa-Saito, M., Fujita, M., Galloway, D.A., Kiyono, T. Immortalization of human epithelial cells by hTERT and inhibition of p16Ink4A either by bmi-1 or RNA interference.  Cancer Science 98:147-154.  2007

  131. Xi, L.F., Koutsky, L.A., Hildesheim, A., Galloway, D.A., Wheeler, C.M., Winer, R.L., Ho, J., Kiviat, N.B.  Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers & Prev.  16: 4-10. 2007.

  132. Katzenellenbogen, R. A., Egelkrout, E. M., Vliet-Gregg, P., Gewin, L.C., Gafken, P.R., Galloway, D.A. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6 expressing cells.  J. Virol. 81 (8): 3786-3796.  2007.

  133. Dominguez-Sola, D., Ying, C.Y., Grandori, C., Ruggiero, L., Chen, B., Galloway, D.A., Gu, W., Gautier, J., Dalla-Favera, R.  Non-transcriptional control of DNA replication by c-Myc.  Nature, 448: 445-451.  2007.
  134. Benanti, J.A.*, Wang, M.L.*, Myers, H.E., Robinson, K.L., Grandori, C., Galloway, D.A.  Epigenetic down regulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc. * these two authors contributed equally to the work.  Molecular Cancer Research 5:1181-1189. 2007.

  135. Bedard, K.M., Underbrink, M.P., Howie, H.L., Galloway, D.A.   The E6 oncoprotein of beta-HPVs differentially activate telomerase through an E6AP dependent mechanism and prolong the lifespan of primary keratinocytes.  J. Virol. 82(8):3894-902. 2008.
  136. Underbrink, M.P., Howie, H.L., Bedard, K.M., Galloway, D.A.  The E6 oncoprotein of beta HPVs target Bak for degradation following UV damage and block apoptosis.  J. Virol. 82(21):10408-17. 2008.
  137. Xu, M.*, Luo, W.*, Elzi, D., Grandori, C., Galloway, D.A.  NFX1 represses hTERT transcription by recruiting the Sin3A co-repressor. * these two authors contributed equally to the work.  Mol. Cell. Bio. 28(15):4819-28.  2008.
  138. Hussain, S.K., Madeleine, M. M., Johnson, L. G., Du, Q., Malkki, M., Wilkerson, H. W., Farin, F. M., Carter, J.J., Galloway, D.A., Daling, J. R., Petersdorf, E. W., Schwartz, S. M. Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2. Cancer Epidemiol Biomarkers Prev. 17(7):1790-9. 2008.
  139. Madeleine, M.M., Johnson, L., Smith, A.J., Nelson, J.L., Schwartz, S.M., Daling, J.R., Galloway, D.A.A comprehensive study of the risk of squamous cell cervical cancer associated with HLA class I and II alleles, inferred haplotypes and allele combinations.  Cancer Research 68(9):3532-9.  2008.
  140. Xi, L. F., Kiviat, N.B., Galloway, D.A., Zhou, X.H., Ho, J., Koutsky, L.A.  Effect of cervical cytology on detection of cervical intraepithelial neoplasia grade III by quantitative analysis of human papillomavirus type 16 DNA. J Infect Dis. 198(3):324-31. 2008.
  141. Xi, L.F., Koutsky, L.A., Castle, P.E., Wheeler, C.M., Galloway, D.A., Mao, C., Ho, J., Kiviat, N.B.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst. 101:153-161.  2009.

  142. Winer, R.L., Harris, T.G., Xi, L-F., Jansen, K.U., Hughes, J.P., Feng, Q., Ho, J., Lee, S.-K., Carter, J.J., Galloway, D.A., Kiviat, N.B., Koutsky, L.A. Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J. Med. Virol.  81 (4): 713-721.  2009.
  143. Randhawa P, Viscidi, R., Carter, J. J., Galloway, D.A., Culp, T.D., Huang, C., Ramaswami, B., Christensen, N.D. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies.  J. Gen Virol. 90(3): 634-639.  2009.
  144. Katzenellenbogen, R.A., Vliet-Gregg, P., Xu, M., Galloway, D.A.  The PAM2 and R3H domains of NFX1-123 regulate hTERT expression post-transcriptionally.  J. Virol. 83(13): 6446- 6456. 2009.
  145. Robinson, K., Asawachaicharn, N., Galloway, DA, Grandori, C.  c-Myc accelerates S-phase and requires WRN to avoid replication stress.  PloS One.  Jun 18; 4(6): e5951.  2009.
  146. Carter, J. J., Miranda, D., Wipf, G.C., Madeleine, M.M., Johnson, L.G., Lemos, B.D., Warcola, A.H., Iyer, J. G., Paulson, K.G., Nghiem, P., Galloway, D.A.  Antibodies to polyomaviruses are common in the general population but only antibodies to Merkel cell virus are associated with Merkel cell carcinoma.  J. Natl. Cancer Inst. 101(21):1510-22.  2009.
  147. Rowhani-Rahbar, A., Carter, J.J., Hawes, S.E., Hughes, J.P., Weiss, N.S., Galloway, D.A., Koutsky, L.A.  Detection of HPV 16 antibodies in oral exudates from vaccine recipients.  J. Infect. Dis.  200(9): 1452-1455. 2009.
  148. Jiang, M., Xi, L. F., Edelstein, Z. R., Galloway, D.A., Olsem, G.J., Lin, W. C-C., Kiviat, N.B.  Identification of recombinant human papillomavirus type 16 variants.  Virology, 394 (1): 8-11.  2009.
  149. Edelstein, Z.R., Madeleine, M.M., Hughes, J.P., Johnson, L.C., Schwartz, S.M., Galloway, D.A., Koutsky, L.A.  Age of Diagnosis of squamous cell cervical carcinoma and early sexual experience. Cancer Epidemiol Biomarkers & Prev. 18(4):1070-1076.  2009.  
  150. Xu, M., Katzenellenbogen, R.A., Grandori, C., Galloway, D.A. NFX1 plays a role in HPV 16 E6-activation of NFkB activity through binding to the p105 promoter.  J. Virol.  84(21): 11461-11469.  2010.
  151. Paulson, K.G.*, Carter, J.J.*, Johnson, L.G., Cahill, K., Wipf, G.C., Iyer, J.,   Schrama, D., Becker, J., Madeleine, M., Nghiem*, P., Galloway*, D.A.   Antibodies to Merkel cell polyomavirus oncoproteins reflect Merkel cell carcinoma tumor burden.  Cancer Research, 70 (21):8388-8397. 2010.
  152. Katzenellenbogen, R.A., Vliet-Gregg, P., Xu, M., Galloway, D.A.  Cytoplasmic poly (A) binding proteins regulate telomerase activity and cell growth in human papillomavirus 16 E6 expressing keratinocytes.  J. Virol. 84 (24):2934-2944.  2010.
  153. Johnson, L.G., Schwartz, S.M., Malkki, A.M., Du, Q., Petersdorf, E.W., Galloway, D.A., Madeleine, M.M.  Risk of invasive squamous cell cervical cancer associated with pollen allergies and polymorphisms in the genes in the chromosome 5 cytokine cluster and their receptors. Cancer Epidemiol Biomarkers Prev. 20 (1) :199-207.  2011.
  154. Paulson, K.G., Iyer, J., Tegeder, A., Thibodeau, R., Schelter, J., Koba, S., Schrama, D., Simonson, W., Lemos, B., Byrd, D., Koelle, D.M., Galloway, D.A., Leonard, J.H., Madeleine, M., Argenyi, Z., Disis, M.L., Becker, J., Cleary, M., Nghiem, P.  Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.  J. Clinical Oncology.  29(12): 1539-1546. 2011.
  155. Xi, L.F., Hughes, J.P., Castle, P.E., Edelstsein, Z.R., Wang, C., Galloway, D.A., Koutsky, L.A., Kiviat, N.B., Schiffman, M., Viral load in the natural history of human papillomavirus type 16 infection: a nested case control study. J. Infect Dis. 203(10): 1425-1433.  2011.
  156. Edelstein, Z.R., Carter, J.J., Garg, R., Winer, R.L., Feng, Q., Galloway*, D.A. Koutsky*, L.A. Serum antibody response following alpha9 HPV infection in young men.  J. Infect. Dis.  204(2):209-216.  2011.
  157. Wang, M.L., Walsh, R., Robinson, K.L., Galloway, D.A., Grandori, C.  Gene expression signature of c-Myc-immortalized human fibroblasts reveals loss of growth inhibitory response to TGF-ß. Cell Cycle, Aug 1:10(15):2540-8. 2011.
  158. Howie, H.L., Koop, J.I., Weese, J., Robinson, K., Wipf, G., Kim, L., Galloway, D.A. Beta HPV 5 and -8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog 7(8): e1002211.  2011.
  159. Iyer, J., Afanasiev, O., McClurkan, C., Paulson, K., Nagase, K., Jing, L., Marshak, J., Dong, L., Carter, J., Lai, I., Farrar, E., Byrd, D., Galloway, D., Yee, C., Koelle, D. Nghiem, P. Toward immunotherapy for Merkel cell carcinoma: Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood.  Clinical Cancer Research. Nov 1;17(21):6671-80. 2011.
  160. Burnett-Hartman, A.N., Newcomb, P.A., Schwartz, S.M., Mandelson, M.T., Galloway, D.A., Carter, J.J., Madeleine, M.M., Makar. K.W., Wurscher, M.A., Potter, J.D.  No evidence for human papillomavirus in the etiology of colorectal polyps. Cancer Epidemiol Biomarkers & Prev. Oct;20(10):2288-97. 2011.
  161. Wallace, N. A., Robinson, K.L., Howie, H.L., Galloway, D.A.  HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage: PloS Pathogens 8(7): e 1002807. 2012.
  162. Stott-Miller, M., Chen, C., Doody, D.R. Carter, J.J. Galloway, D.A., Madeleine, M.M. Schwartz, S.M. A history of allergies is associated with reduced risk of oral squamous cell carcinoma.  Cancer Causes and control 23(12):1911-1919.  2012.
  163. Madeleine, M.M., Johnson, L.G., Daling, J.R., Schwartz, S.M., Carter, J.J., Porter, P.L., Fishbein, D., Berg, D., Nelson, K., Davis, C.L., Galloway, D.A. Cohort profile: the skin cancer after organ transplant study.  Int. J of Epid. 2012: 1-9.  2012.
  164. Hussain, S.K., Madeleine, M.M., Johnson, L.G., Du, Q., Carter, J.J., Galloway, D.A., Daling, J.R., Malkki, M., Petersdorf, E.W., Schwartz, S.M.  Nucleotide variation in IL10 and IL12 and their receptors and cervical and vulvar cancer risk: a hybrid case-parent triad and case-control study.  Int J Cancer. 2012 Dec 22. doi: 10.1002/ijc.28000. [Epub ahead of print].
  165. Moscicki, A.-B., Ma, Y., Nozzari, S., Darragh, T.M., Pawlita, M., Galloway, D.A., Shiboski, S.  Redetection of cervical HPV 16 in a longitudinal cohort of women with a previous history of HPV 16. J. Infect. Dis. 208(3): 403-412. 2013.
  166. Wallace, N.A., Gasior, S.L., Faber, Z.J., Howie, H.L., Deininger, P.L., Galloway, D.A. HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition. Virology. 443(1):69-79.  2013.
  167. *Carter, J.J.*, Daugherty, M.D.*, Qi, X., Bheda-Malge, A., Wipf, G.C., Robinson, K., Roman, A., Malik, H.S., Galloway, D.A. Identification of an overprinting gene in Merkel Cell polyomavirus provides evolutionary insight into the birth of viral genes.   Proc Natl Acad Sci USA. 30; 110 (31):12744-9. 2013.
  168. *Xu, M., * Katzenellenbogen, R.A., Grandori, C., Galloway, D.A. An unbiased in vivo screen reveals multiple transcription factors that control HPV E6-regulated hTERT in keratinocytes.  Virology, 446:17-24. 2013.
  169. Bodelon, C., Madeleine, M.M., Johnson, L.G., Du, Q., Galloway, D.A., Malkki, M., Petersdorf, E.W., Schwartz, S.M.  Genetic variation in the TLR and NF-κB pathways and cervical and vulvar cancer risk: A population-based case-control study.  Int J Cancer.  134(2):437-444. 2014.
  170. Wallace, N.A., Robinson, K.L., Galloway, D.A. Beta Human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability. J. Virol. 88 (11): 6112-6127.  2014.
  171. Madeleine, M.M., Carter, J.J., Johnson, L.G., Wipf, G.C., Davis, C., Berg, D., Nelson, K., Daling, J. R., Schwartz, S.M., Galloway, D.A.  Risk of squamous cell skin cancer in organ transplant recipients associated with antibodies to cutaneous papillomaviruses, polyomaviruses and TMC6/8 (EVER1/2) variants.  Cancer Medicine. Oct;3(5):1440-7. 2014.
  172. Winer, R. L., Huang, C.E., Cherne, S., Stern, J.E., Butsch Kovacic, M.S., Mehta, P.A., Sauter, S.L., Galloway, D.A., Katzenellenbogen, R.A. Detection of human papillomavirus in the oral cavities of persons with Fanconi Anemia.  Oral Dis. 3: 349-54. 2014
  173. *Scherer, E., M., Smith, R.A., Simonich, C.A., Niyonzima, N., Galloway, D.A.  Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathogens.  Oct 16;10(10): e1004461. doi: 10.1371/journal.ppat.1004461. eCollection 2014 Oct. 2014.
  174. Wallace, N.A., Robinson, K.L., Galloway, D.A. Beta-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation.  PLoS Pathog. Mar;11(3): e1004687 eCollection March.  2015.
  175. Katzenellenbogen, R.A., Carter, J.J., Stern, J., Kovacic, M.B., Mehta, P., Sauter, S., Galloway, D.A., Winer, R. Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia.  Clinical and Vaccine Immunology.  Apr;22(4):413-20. 2015.
  176. Colombara, D.V., Hughes, J.P., Burnett-Hartman, A.N., Hawes, S.E., Galloway, D.A., Schwartz, S.M., Bostick, R.M., Potter, J.D., Manhart, L.E. Analysis of liquid bead microarray antibody assay data for epidemiologic studies of pathogen-cancer associations. J Immunol Methods. 425: 45-50. 2015.
  177. Hardikar, S., Johnson, L.G., Malkki, M., Petersdorf, E.W., Galloway, D.A., Schwartz, S.M., Madeleine, M.M. A population-based case-control study of genetic variation in cytokine genes associated with risk of cervical and vulvar cancers. Gynecol Oncol. 139: 90-96. 2015.
  178. Colombara, D.V., Manhart, L.E., Carter, J.J., Hawes, S.E., Weiss, N.S., Hughes, J.P., Barnett, M.J., Goodman, G.E., Smith, J.S., Qiao, Y.L., Galloway, D.A.  Prior human polyomavirus and papillomavirus infection and incident lung cancer: a nested case-control study. Cancer Causes Control. 26(12): 1835-1844. 2015.
  179. Sadate-Ngatchou, P., Carter, J.J., Hawes, S.E., Feng, Q., Lasof, T., Stern, J.S., Fu, T-c., Galloway, D.A., Koutsky, L.A., Winer, R.L. Determinants of high-risk HPV seroprevalence and DNA prevalence in mid-adult women.  Sexually Transmitted Dis., 43(3): 192-198, 2016.
  180. Xi L.F, Schiffman M, Koutsky LA, Hughes JP, Hulbert A, Shen Z, Galloway DA, Kiviat NB. Variant-specific persistence of infections with human papillomavirus types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia. Int. J Cancer 139(5): 1098-1105.  2016.
  181. Madeleine, M.M., Johnson, L.G., Doody, D.R., Tipton, E.R., Carter, J.J., Galloway, D.A. Natural Antibodies to Human Papillomavirus 16 and Recurrence of Vulvar High-Grade Intraepithelial Neoplasia (VIN3).  J Low Genit Tract Dis. 20: 257-60. 2016.
  182. Colombara, D.V., Manhart, L.E., Carter, J.J., Hawes, S.E., Weiss, N.S., Hughes, J.P., Qiao, Y.L., Taylor, P.R., Smith, J.S., Galloway, D.A. Absence of an association of human polyomavirus and papillomavirus infection with lung cancer in China: a nested case-control study. BMC Cancer. Jun 1;16(1):342. 2016.
  183. Scherer, E.M., Smith, R.A., Gallegos, D.F., Carter, J.J., Wipf, G., Hoyos, M., Stern, M., Wald, A. Galloway, D.A.  A single HPV vaccine dose Improves B cell memory in previously infected subjects.  eBiomedicine.  doi: 10.1016/j.ebiom.2016.06.042. 2016
  184. Fu, T-C., Carter, J.J., Hughes, J.P., Feng, Q., Hawes, S.E., Schwartz, S.M., Xi, L.F., Lasof, T., Stern, J.E., Galloway, D.A., Koutsky, L.A., Winer, R.L.  Re-detection versus new acquisition of high risk human papillomavirus in mid-adult women.  Int. J. Cancer, 139(10): 2201-2212. 2016.
  185. Jardine, J.G., Sok, D., Julien, J.-P., Briney, B., Sarkar, A., Liang, C.-H., Scherer, E.M., Dunand, C.J. H., Adachi, Y., DiWanji, D., Hsueh, J., Jones, M., Kalyuzhnly, O., Kubitz, M., Spencer, S., Pauthner, M. Saye-Francisco, K.L., Sesterhenn, F., Wilson, P.C., Galloway D.A., Stanfield, R.L., Wilson, I.A., Burton, D.R., Schlief, W.R., Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design.  PLoS Pathogens 12:(9) e1005815. doi: 10.1371/journal.ppat.1005815.  2016.
  186. Xi, L.F., Schiffman, M., Ke, Y., Hughes, J.P., Galloway, D.A., Hulbert, A., Winer, R.L., Kiviat, N.B.  Type dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.  Int J. Cancer, Apr 15;140(8):1747-1756. 2017.

  187. Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer. 123 (8): 1464-1474. 2017.
  188. Wallace, N.A., Khanal, S., Robinson, K.L., Wendel, S.O., Messer, J.J., Galloway, D.A., High risk alpha papillomavirus oncogenes impair the homologous recombination pathway.  J Virol. 2017 Sep 27;91(20). pii: e01084-17. doi: 10.1128/JVI.01084-17. Print 2017 Oct 15. 

  189. Scherer, E.M., Smith, R.A., Carter, J.J., Wipf, G.C., Gallego, D.F., Stern, M., Wald, A., Galloway, D.A.  Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine. J. Infec. Dis.  2018 Jan 30;217(4):572-580 PMC5853470
  190. Tan, N., Sharma, M., Winer, R., Galloway D., Barnabas, R.V. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.  Vaccine 2018 36 (32ptA) 4830-4836.
  191. Mugo, N., Eckert, L., Magaret, A.S., Cheng, A., Mwaniki, L., Ngure, K., Celum, C., Baeten, J., Galloway, D.A., Wamalwa, D., Wald, A. Quadrivalent HPV vaccine in HIV infected early adolescent girls and boys in Kenya: Month 7 and 12 post-vaccine immunogenicity and correlation with immune status. Vaccine 12;36(46):7025-7032.2018.
  192. Dye, K.N., Welcker, M., Clurman, B.E., Roman, A., Galloway, D.A. Merkel Cell polyomavirus tumor antigens expressed in Merkel Cell carcinoma function independently of the ubiquitin ligases Fbw7 and b-TrCP.  PLoS Pathogens, Jan 28;15(1):e10075.  2019.   
  193. Khanal, S., Galloway, D.A. High risk human papillomavirus oncogenes disrupt the Fanconi Anemia DNA repair pathway by impairing foci formation and de-ubiquitinylation of FancD2.  PLoS Pathogens PLoS Pathog. Feb 28;15(2):e1007442. 2019
  194. Stankiewicz Karita, H., Hauge, K., Magaret, A., Mao, C., Shouten, J., Galloway, D.A., Madeline, M. Wald, A. Human papillomavirus vaccine to interrupt recurrence of vulvar and anal neoplasia (VIVA trial): a trial protocol.  JAMA Network Open Journal, Apr 5;2(4):e190819, 2019

B. Book Chapters

  1. Sambrook, J., Galloway, D.A., Topp, W.C.  and Botchan, M.  The arrangement of viral DNA sequences in the genomes of cells transformed by SV40 or adenovirus 2.  International Cell Biology 1976-1977.  (B.R. Brinkley and K.R. Porter, eds.)  The Rockefeller University Press, New York, pp. 539-553.  1977.
  2. McDougall, J.K. and Galloway, D.A.  Detection of viral nucleic acid sequences using in situ hybridization.  In “Persistent Viruses,” Vol. 11 (Stevens, J., Todaro, G., and Fox, C.F., eds.)  Academic Press, New York.  pp. 181-188.  1978.
  3. McDougall, J.K., Galloway, D.A. and Fenoglio, C.M.  In situ cytological hybridization to detect herpes simplex virus RNA in human tissues.  In “Antiviral Mechanisms for the Control of Neoplasia.”  NATO.  International Advances Study Institute (Chandra, P. ed.)  Plenum Press, New York.  pp. 223-241.  1979.
  4. McDougall, J.K., Galloway, D.A., Purifoy, D.J.M., Powell, K.L., Richart, R. and Fenoglio, C.  Herpes simplex virus expression in latently infected ganglion cells and in cervical neoplasia.  In “Viruses in Naturally Occurring Cancer.”  Cold Spring Harbor Press, NY pp. 101-116.  1979.
  5. McDougall, J.K. and Galloway, D.A.  Footprints of herpes simplex virus in transformed cells and in cervical carcinoma.  In “The Human Herpesviruses”: (ed. A.J. Nahmias).  Elsevier North Holland Press.  pp. 245-250.  1981.
  6. Fenoglio, C.M., Galloway, D.A., Crum, C.P., Levine, R.U., Richart, R.M.  and McDougall, J.K.  Herpes simplex virus and cervical neoplasia.  In “Progress in Surgical Pathology” Vol. 4 (eds. C.M. Fenoglio and M. Wolff).  Masson Publishing, NY.  pp. 45-82.  1981.
  7. McDougall, J.K. and Galloway, D.A.  In situ cytological hybridization in diagnostic pathology.  In “Progress in Surgical Pathology” Vol. 4 (eds. C.M. Fenoglio and M. Wolff) Masson Publishing, NY.  pp. 83-94.  1981.
  8. McDougall, J.K., Smith, P., Tamimi, H.K., Tolentino, E. and Galloway, D.A.  Molecular biology of the relationship between herpes simplex virus-II and cervical cancer.  In “The Role of Viruses in Human Cancer” (Giraldo, G. and Beth, E. eds.) Elsevier, Amsterdam pp. 59-71.  1984.
  9. McDougall, J.K., Beckmann, A.M., Galloway, D.A., Nelson, J.A. and Myerson, D.  Defined viral probes for the detection of HSV, CMV and HPV.  in “Rapid Detection and Identification of Infectious Agents” (D.T. Kingsbury and S. Falkow, eds.)  Academic Press, NY. pp. 89-107.  1984.
  10. Galloway, D.A., Nelson, J.A. and McDougall, J.K.  Morphological transformation by herpes simplex virus type 2 and cytomegalovirus.  Schering/UCLA Symp. on AIDS, Allan R. Liss Press pp. 157-174.  1984.
  11. McDougall, J.K., Buonaguro, F.M., Galloway, D.A., Nelson, J.A. and Smith, P.  DNA virus and EM studies in AIDS.  Schering/UCLA Symp. on AIDS, Alan R. Liss Press pp. 139-156.  1984.
  12. Ben-Porat, T., Deatly, A.M., Easterday, B.C., Galloway, D.A., Kaplan, A.S. and McGregor, S.  Latency of Pseudorabies virus, in: Current topics in Veterinary Medicine and Animal Science (G. Wittman, R.M. Gaskell and H.-J. Rhiza eds).  Marinus Niujhoff Publishers, pp. 365-383.  1984.
  13. McDougall, J.K. and Galloway, D.A.  Relationship of herpes simplex to dysplasia in “Interferon in the Prevention of Cervical Carcinoma.”  NIH Monograph.  pp. 68-78.  1985.
  14. McDougall, J.K., Beckmann, A.M. and Galloway, D.A.  The enigma of viral nucleic acids in genital neoplasia.  in “Viral Etiology of Cervical Cancer” (R. Peto and H. Zur Hausen. eds).  Banbury Conference, Cold Spring Harbor, NY. pp. 199-209.  1985.
  15. Galloway, D.A., Buonaguro, F.M., Brandt, C.R. and McDougall, J.K.  Herpes simplex virus and cytomegalovirus: Unconventional DNA Tumor Viruses in “Cancer Cells: Volume 4 DNA Tumor Viruses: Control of Gene Expression and Replication” eds. T. Grodzicker, P. Sharp, M. Botchan.  Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 355-361.  1986.
  16. Brandt, C.R., McDougall, J.K. and Galloway, D.A.  Synergistic interactions between human papillomavirus type 18 sequences, herpes simplex virus infection and chemical carcinogen treatment.  in “Cancer Cells: Volume 5 Papillomaviruses” eds. B. Steinberg, J. Brandsma, L. Taichman.  Cold Spring Harbor Press, Cold Spring Harbor Laboratory, N.Y. pp. 179-186. 1987.
  17. Firzlaff, J.M., Hsia, C.-N., Halbert, C.P.L., Jenison, S.A. and Galloway, D.A.  Polyclonal antibodies to human papillomavirus type 6 and 16 bacterially derived fusion proteins.  in “Cancer Cells: Volume 5 Papillomaviruses” eds. B. Steinberg, J. Brandsma, L. Taichman.  Cold Spring Harbor Press, Cold Spring Harbor Laboratory, N.Y. pp. 105-113.  1987.
  18. Buonaguro, F.M., Taeschner, A., McDougall, J.K. and Galloway, D.A.  Transforming properties of human cytomegalovirus.  Human Tumor Markers eds. Cimino, Birkmayer, Klavins, Pimentel, Selvatore.  Walter de Gruyter & Co., Berlin-New York.  pp. 129-147.  1987.
  19. McDougall, J.K., Beckmann, A.M., Kaur, P., Galloway, D.A.  DNA viruses in anogenital cancer.  in “Medical Virology VI” ed. L. de la Maza and E.M. Peterson.  Elsevier, B.V.  pp. 261-283. 1987.
  20. Galloway, D.A. and McDougall, J.K.  Human papillomaviruses and carcinomas.  Adv. in Virus Res. 37:125-171.  1989.
  21. Galloway, D.A.  Serological assays for the detection of HPV antibodies.  In: “The epidemiology of human papillomavirus and cervical cancer.”  IARC Press #119, eds. N. Muñox, F.X. Bosch, K.V. Shah and A. Meheus.  pp. 147-162.  1992.
  22. Galloway, D.A., McDougall, J.K.  Disruption of cell cycle checkpoints by HPV oncogenes contributes to anogenital malignancy.  in “Human Papillomaviruses:  Seminars in Cancer Biology”.  7:309-315. 1996.
  23. Shoultz, D.A., Koutsky, L.A. and Galloway, D.A.  Epidemiology and modes of transmission.  in “Human Papillomavirus Infections in Dermatovenereology” CRC Press eds.  G. von Krogh and G. Gross.  pps. 83-100.   1997.
  24. Carter, J.J., Galloway, D.A.  Humoral Immunity to HPV.  in “Papillomaviruses: Clinics in Dermatology” eds. S. Jablonska and G. Orth, Elsevier Science. Vol. 15:249-259.  1997.
  25. Galloway, D. A., Biology of genital human papillomaviruses.  in “Sexually Transmitted Diseases”, third edition, editors K.K. Holmes, P.F. Sparling, P.A. Mardh, S.M. Lemon, W.E. Stamm, P.Piot,  J.N. Wasserheit,  McGraw Hill Publishers, Chapter 24, pps. 335-346. 1998.
  26. Egelkrout, E.M., Galloway, D.A. The humoral immune response to human papillomavirus.  In Papillomaviruses, ed. R. Garcea and D. DiMaio, Springer Science.  Chapter 12, pps 277-312.  2007.

  27. Egelkrout, E. M., Galloway, D. A., Biology of genital human papillomaviruses.  in “Sexually Transmitted Diseases, 4th edition”, editors K.K. Holmes, P.F. Sparling, W.E. Stamm, P.Piot, J.N. Wasserheit , L. Corey, M. Cohen, H. Watts,  McGraw Hill Publishers.  Chapter 27, pps 463-488.  2007.
  28. Katzenellenbogen, R.A., Galloway, D.A.  “HPV Associated Cancers” in Viral Oncology: Basic to    Clinical Perspectives.  Eds. K. Khalili and K.-T. Jeang.  Wiley-Blackwell. Chapter 1, pps 1-22. 2009.

C. Published Books:  None.

D. Other Publications

  1. McDougall, J.K., Nelson, J.A., Myerson, D., Beckmann, A.M.  and Galloway, D.A.  HSV, CMV and HPV in Human Neoplasia.  J. Invest. Dermatology 83:72-76.  1984. [invited review].
  2. Koutsky, L., D.A. Galloway, K.K. Holmes.  The epidemiology of genital papillomavirus infections.  Epidemiol. Reviews 10:122-163.  1988. [review]
  3. Galloway, D.A. and Jenison, S.A.  Characterization of the humoral immune response to genital papillomaviruses.  Molec. Biol. and Medicine 7:59-72.  1990. [invited review].
  4. Galloway, D.A.  HPV Serology: an update.  Papillomavirus Report 1(2): 1-3.  1990. [invited review]
  5. Hagensee, M.E. and Galloway, D.A.  Growing human papillomaviruses and virus-like particles in the laboratory.  Papillomavirus Report 4:121-122.  1993. [invited review]
  6. Galloway, D.A., Demers, G.W., Foster, S.A., Halbert, C.L. and Russell, K.   Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes.  In Cold Spring Harbor Symp. Quant. Biol., The Molecular Genetics of Cancer 59:  297-306.   1994. [invited review].
  7. Galloway, D.A. Navigating the descent into papillomavirus hell.  J. Infect. Dis.  170: 1075-1076. 1994. [editorial]
  8. Galloway, D.A.  Human papillomavirus vaccines: a warty problem.  Infectious Agents and Disease.      3: 187-193.  1994. [invited review]
  9. Galloway, D.A. Papillomavirus capsids: a new approach to identify serological markers of HPV infection.  (editorial).   J. Natl. Cancer Inst.  86: 474-475.  1994. [editorial]
  10. Daling, J.R., Madeleine, M.M., McKnight, B., Carter, J.C. Schwartz, S.M., Beckmann, A.M., Mandelson, M.T., Galloway, D.A.  The relationship of human papillomavirus – related cervical tumors to cigarette smoking, oral contraceptive use and prior herpes simplex -2 infection.  Proceedings of the Jakarta International Cancer Congress. 1995. [invited manuscript].
  11. Galloway, D.A.  HPV Serology: another update.  in Papillomavirus Reviews.  editor CJN Lacey, Royal Soc. of Med. Press, London.   pp113-120.  1996. [invited review].
  12. Galloway, D.A. Papillomavirus oncoproteins as vaccine candidates (commentary).  The Lancet 347: 1498-1499.  1996. [invited review].
  13. Hagensee, M.E. and Galloway, D.A.  Growing human papillomaviruses and virus-like particles the laboratory. in Papillomavirus Reviews.  editor CJN Lacey, Royal Soc. of Med. Press, London. pps 85-92. 1996. [invited review]
  14. Galloway, D.A., Daling, J.R.  Is the evidence implicating HPV16 in the etiology of esophageal cancer hard to swallow? J. Natl. Cancer Inst.  88:1421-1423.  1996. [editorial]
  15. Galloway, D.A., Halbert, C.L, Demers, G.W., Foster, S.A., Blanton, R.A., Merrick, D., Klingelhutz, A. and McDougall, J.K.  Use of amphotropic retroviruses expressing HPV 16 E6 and E7 to determine the consequences of acute expression of the viral oncogenes and to establish immortalized human cell lines. Radiation Oncology Investigations 3: 315-319.  1996. [invited review].
  16. Galloway, D.A.  Is a vaccine for human papillomavirus a possibility? Sexually Transmitted Diseases Supplement, Lancet 351 (suppl III) 22-24. 1998. [invited review]
  17. Funk, J.O., Galloway, D.A. Inhibiting CDK inhibitors: new lessons from DNA tumor viruses.  Trends in Biochem. Sci.  9: 337-341. 1998. [invited review]
  18. Galloway, D.A.  Papillomavirus vaccines in clinical trials.  The Lancet, Infectious Diseases. Review 3(8):469-75. 2003. [invited review]
  19. Galloway, D.A., Gewin, L.C., Myers, H., Luo, W., Grandori, C., Katzenellenbogen, R. A., McDougall, J.K.  Regulation of telomerase by human papillomaviruses.  Cold Spring Harbor Symposium in Quantitative Biology, LXX, Molecular Approaches to Controlling Cancer.  CSHL Press. pps 209-215.  2005. [invited manuscript]
  20. Howie, H., Katzenellenbogen, R.A., Galloway, D.A. Papillomavirus E6 proteins.  Virology, 384: 324-334. 2009. [invited review].
  21. Galloway, D.A.  Human papillomaviruses: a growing field.  Genes and Development, 23: 138-142, 2009.  [commentary].
  22. Carter, J.J., Galloway, D.A. Stopping HPVs dead in their tracts.  Cell Host & Microbe 8 (3): 221-222. 2010. [invited review]

  23. Wallace, N.A., Galloway, D.A.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses, Seminars in Cancer Biology.  26C:30-42. 2014. [invited review]
  24. Galloway, D.A., Laimins, L.A. Human papillomaviruses: shared and distinct pathways for pathogenesis.  Current Opinion in Virology 14: 87-92. 2015. [invited review]
  25. Wallace N.A., Galloway D.A. Novel functions of human papillomavirus E6 oncoproteins. Annual Rev Virol. 2(1):403-23.  2015. [invited review].

  26. Galloway, D.A. The Murky Life of Merkel Cell Polyomavirus. Cell Host Microbe. Jun 8;19(6):747-748.  2016. [commentary].

E. Manuscripts Submitted:  None currently.

Plenaria

HPV Associated Cancers and the HPV Vaccine

Denise A. Galloway, Director, Pathogen Associated Malignancies Integrated Research Center, Paul Stephanus Memorial Endowed Chair, Member Human Biology and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

A group of about 15 high risk types of human papillomaviruses (HR-HPV) account for nearly all cervical cancers and the majority of other anogenital and oropharyngeal cancers. HPV infection is common among young sexually active individuals. While greater than 90% of infected women control their infections, persistent HPV lesions are a precursor for the development of cervical cancer. Three extremely effective vaccines are available that contain virus like particles (BVLPs) of bi-, quadri-, and nonavalency. VLPs consist solely of the major capsid protein, L1, of the HPV types, i.e. 9vHPVcontains VLPs from HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58. Current studies are evaluating the generation of long-term memory by the vaccines and reducing the number of doses.

Cánceres asociados al VPH y la vacuna contra el VPH

Denise A. Galloway, Directora, Centro de Investigación Integrada de Patologías Asociadas de Enfermedades Malignas Asociadas, Paul Stephanus Memorial, Directora Dotada, Miembro de la División de Biología Humana y Ciencias de la Salud Pública, Centro de Investigación del Cáncer Fred Hutchinson, Seattle, WA, EE.UU.

Un grupo de aproximadamente 15 tipos de virus del papiloma humano (HR-HPV, por sus siglas en inglés) de alto riesgo representan casi todos los cánceres de cuello uterino y la mayoría de los otros cánceres anogenitales y orofaríngeos. La infección por VPH es común Mientras que más del 90% de las mujeres infectadas controlan sus infecciones, las lesiones persistentes de HPV son un precursor para el desarrollo de cáncer cervical. Hay tres vacunas extremadamente efectivas disponibles que contienen partículas similares a virus (BVLP) de bi-, quadri- y nonvalency. Las VLP solo incluyen la proteína de la cápside principal, L1, de los tipos de VPH, es decir, 9vHPV contiene VLPs de HPV 6, 11, 16, 18, 31, 33, 45, 52 y 58. Los estudios actuales están evaluando la generación de memoria a largo plazo por las vacunas y la reducción del número de dosis.

Publicado en Sin categoría.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *